Magnetic Nanoparticles Offer a Heat-Based Path to Treating Ectopic Pregnancy

An ectopic pregnancy is one of the most feared complications in early obstetric care. It occurs when a fertilized egg implants somewhere other than the lining of the uterus, most often inside a fallopian tube, where there is no room for a pregnancy to grow. Because such pregnancies are never viable and can rupture the tube and trigger catastrophic hemorrhage, they remain a leading cause of maternal death in the first trimester. Now a research team led by an Oregon State University scientist has demonstrated, in a mouse model, a potentially better way of caring for women facing this life-threatening condition: a single magnetic nanoparticle designed to both diagnose and treat the condition, published in the journal Biomaterials and primarily funded by the National Cancer Institute of the National Institutes of Health.

The scale of the problem is considerable. According to the authors, roughly 2 percent of all pregnancies in the United States, and between 1 and 2 percent worldwide, are ectopic. In the United States alone, that translates to approximately 100,000 ectopic pregnancies each year, and over the past six years about 30 women have died annually from the condition. About 98 percent of ectopic implantations happen in the fallopian tubes, placing women at direct risk of tubal rupture, internal bleeding and death. The clinical stakes are compounded by the limitations of the tools currently available to detect and end these pregnancies, which are far from perfect even in well-resourced health systems.

The standard diagnostic tool, transvaginal ultrasound, carries a misdiagnosis rate of about 10 percent, meaning a meaningful fraction of ectopic pregnancies are either missed or incorrectly identified. The primary drug used to end an ectopic pregnancy, methotrexate, has an even higher failure rate. Methotrexate works by causing embryonic cells to stop dividing, but even when it is effective it comes with a range of potential side effects, including nausea, vomiting, diarrhea, elevated liver enzymes, kidney damage and lung disease. When medication fails or diagnosis comes too late, surgery becomes necessary, and surgery on the fallopian tube carries its own consequences for future fertility.

Olena Taratula of the OSU College of Pharmacy, who led the study, framed the shortcomings of the current standard of care bluntly. Current strategies, she said, which involve attempted diagnosis via ultrasound, treatment with methotrexate, and surgery if necessary, are associated with the risk of tubal rupture and reduced fertility. She also noted an increased risk of recurrence: a woman who has had one ectopic pregnancy is 10 percent more likely to have a second one. Together, these factors create a clinical landscape in which earlier, more accurate diagnosis and less destructive treatment options could meaningfully improve outcomes for tens of thousands of women each year.

The alternative explored by Taratula, postdoctoral scholar Karthickraja Duraisamy and collaborators at Oregon State and Oregon Health & Science University is a nanomedicine approach built on specially engineered magnetic nanoparticles. Nanoparticles are tiny pieces of matter, as small as one-billionth of a meter, small enough to travel through the bloodstream and accumulate in specific tissues. The particles developed for this study are cobalt-doped soft ferromagnetic iron oxide nanoparticles, administered intravenously. In pregnant mice, the particles accumulated in the placenta, the organ that nourishes and maintains the fetus through the umbilical cord, and that selective accumulation is the key to both halves of the platform.

The diagnostic function exploits that accumulation directly. Once the nanoparticles are concentrated in placental tissue, the organ can be clearly seen through magnetic resonance imaging. Effective detection of the growing placenta, Taratula explained, greatly improves the accuracy and timeliness of ectopic pregnancy identification. In a human patient, an MRI scan after particle administration would quickly reveal whether the placenta is where it is supposed to be. If it is, the patient would know she does not have an ectopic pregnancy, and the embryo would be unaffected by the particles, which do not cross the placental barrier. If the placenta is instead located in a fallopian tube or another incorrect site, the same scan provides a precise target for treatment.

That treatment is where the magnetic properties of the particles come into play. When exposed to an alternating magnetic field, the cobalt-doped iron oxide nanoparticles heat up. This magnetic hyperthermia is deliberately controlled: the team developed an MRI-guided magnetic nanoplatform for localized hyperthermia of pregnancy-associated tissue at temperatures of less than or equal to 45 degrees Celsius. At that temperature, applied non-invasively from outside the body, the heat irreparably disrupts placental function, ending the pregnancy without drugs and without incisions. Because the heat is generated only where the particles have accumulated, the thermal effect is confined to the misplaced gestational tissue rather than the surrounding anatomy.

The results in the animal model were striking. In pregnant mice, the platform selectively disrupted gestational sacs while preserving surrounding uterine tissue and fertility, according to Duraisamy, who said the findings support its potential as a minimally invasive treatment for ectopic pregnancy. Preserving fertility is a central goal, given that surgical removal of part or all of a fallopian tube is a known driver of both reduced fertility and the elevated risk of future ectopic pregnancies. A therapy that ends a non-viable pregnancy while leaving the reproductive tract intact would represent a fundamental shift in how the condition is managed.

Taratula emphasized that the study was designed to answer two specific questions: whether the nanoparticle could identify and visualize the developing placenta, and whether it could deliver effective magnetic hyperthermia. Both were demonstrated, and she described the results as highly promising while stressing the road ahead. In the coming years, she said, the team needs to validate the findings in other animal models to further advance the application of this technology. Translation from mice to humans will require establishing safe dosing, particle clearance, imaging protocols and treatment parameters in larger animal studies before any clinical trial could begin, a process that typically spans years.

The research was contributed to by Oleh Taratula, Prem Singh, Akshay Vyawahare, Ana Paula Mesquita Souza and Kongbrailatpam Shitaljit Sharma of Oregon State, and was supported by the College of Pharmacy, the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the OHSU School of Medicine. If the platform continues to perform in further preclinical work, it could eventually offer clinicians a single intravenous agent that answers the two most urgent questions in suspected ectopic pregnancy, where is the placenta and how can the pregnancy be ended safely, with an MRI scan and a magnetic field rather than a scalpel. For the roughly 100,000 American women each year who face this diagnosis, that combination of certainty and gentleness would mark a profound improvement over the options available today.

Subject of Research: Nanoparticle-mediated MRI diagnosis and magnetic hyperthermia treatment of ectopic pregnancy

Article Title: Researchers push toward improved care for women with dangerous pregnancy condition

Article References: Researchers push toward improved care for women with dangerous pregnancy condition. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: ectopic pregnancy, nanoparticles, magnetic hyperthermia, MRI, iron oxide, placenta, methotrexate, fertility, Oregon State University, Biomaterials, preclinical study, women's health